An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
The primary purpose of this study is to assess the safety and efficacy of repeated
 subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
Inclusion Criteria:

 1. Satisfactory completion of KKP's sponsored KRN23-INT-001 clinical trial

 2. eGFR ≥ 60 mL/min

 3. Corrected Ca < 10.8 mg/dL

 4. For female of child-bearing potential, a negative serum pregnancy test

 5. A willingness to utilize adequate contraception and not become pregnant [or to have
 their partner(s) become pregnant] during the study

 6. Additional inclusion criteria apply

 Exclusion Criteria:

 1. Subject experienced a safety-related event in the KRN23-INT-001 study

 2. Pregnant or lactating female subject or pregnant or female planning to become pregnant
 during the study

 3. Receipt of a live (attenuated) vaccine (except for influenza vaccines) during the
 course of the KRN23-INT-001 study and/or of this study

 4. Condition which could present a concern for either the subject's safety or difficulty
 with data interpretation

 5. Additional exclusion criteria apply